Literature DB >> 24800132

Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison.

Randy A Sansone1, Lori A Sansone1.   

Abstract

The serotonin norepinephrine reuptake inhibitors are a family of antidepressants that inhibit the reuptake of both serotonin and norepinephrine. While these drugs are traditionally considered a group of inter-related antidepressants based upon reuptake inhibition, they generally display different chemical structures as well as different pharmacological properties. In this article, we discuss these and other differences among the serotonin norepinephrine reuptake inhibitors, including the year of approval by the United States Food and Drug Administration, generic availability, approved clinical indications, half-lives, metabolism and excretion, presence or not of active metabolites, dosing schedules, proportionate effects on serotonin and norepinephrine, and the timing of serotonin and norepinephrine reuptake (i.e., sequential or simultaneous). Again, while serotonin norepinephrine reuptake inhibitors are grouped as a family of antidepressants, they exhibit a surprising number of differences- differences that may ultimately relate to clinical nuances in patient care.

Entities:  

Keywords:  Antidepressants; SNRIs; desvenlafaxine; duloxetine; levomilnacipran; milnacipran; selective serotonin reuptake inhibitors; venlafaxine

Year:  2014        PMID: 24800132      PMCID: PMC4008300     

Source DB:  PubMed          Journal:  Innov Clin Neurosci        ISSN: 2158-8333


  13 in total

1.  Milnacipran: an antidepressant with dual selectivity of action on noradrenaline and serotonin uptake.

Authors:  A Delini-Stula
Journal:  Hum Psychopharmacol       Date:  2000-06       Impact factor: 1.672

Review 2.  SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants.

Authors:  Stephen M Stahl; Meghan M Grady; Chantal Moret; Mike Briley
Journal:  CNS Spectr       Date:  2005-09       Impact factor: 3.790

Review 3.  Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder.

Authors:  Melanie E Hunziker; Brandon T Suehs; Tawny L Bettinger; M Lynn Crismon
Journal:  Clin Ther       Date:  2005-08       Impact factor: 3.393

4.  Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor.

Authors:  Darlene C Deecher; Chad E Beyer; Grace Johnston; Jenifer Bray; S Shah; M Abou-Gharbia; Terrance H Andree
Journal:  J Pharmacol Exp Ther       Date:  2006-05-04       Impact factor: 4.030

5.  Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects.

Authors:  J E Turcotte; G Debonnel; C de Montigny; C Hébert; P Blier
Journal:  Neuropsychopharmacology       Date:  2001-05       Impact factor: 7.853

6.  Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety.

Authors:  A L Auclair; J C Martel; M B Assié; L Bardin; P Heusler; D Cussac; M Marien; A Newman-Tancredi; J A O'Connor; R Depoortère
Journal:  Neuropharmacology       Date:  2013-03-13       Impact factor: 5.250

7.  Tolerability of serotonin norepinephrine reuptake inhibitor antidepressants.

Authors:  Stuart A Montgomery
Journal:  CNS Spectr       Date:  2008-07       Impact factor: 3.790

8.  Synthesis and biological activity of some known and putative duloxetine metabolites.

Authors:  F Kuo; T A Gillespie; P Kulanthaivel; R J Lantz; T W Ma; D L Nelson; P G Threlkeld; W J Wheeler; P Yi; M Zmijewski
Journal:  Bioorg Med Chem Lett       Date:  2004-07-05       Impact factor: 2.823

9.  Milnacipran: a unique antidepressant?

Authors:  Siegfried Kasper; Gerald Pail
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

10.  Desvenlafaxine in the treatment of major depressive disorder.

Authors:  Maria Teresa C Lourenco; Sidney H Kennedy
Journal:  Neuropsychiatr Dis Treat       Date:  2009-04-08       Impact factor: 2.570

View more
  10 in total

1.  Drug-induced movement disorder and confusion associated with duloxetine.

Authors:  Sarah Hasan Siddiqui; Nadeem Ahmed Memon; Ravi Shanker
Journal:  BMJ Case Rep       Date:  2018-03-28

2.  Pharmacotherapy for Anxiety Disorders: From First-Line Options to Treatment Resistance.

Authors:  Andrew J Melaragno
Journal:  Focus (Am Psychiatr Publ)       Date:  2021-06-17

Review 3.  Duloxetine in Psychiatric Disorders: Expansions Beyond Major Depression and Generalized Anxiety Disorder.

Authors:  Maria Rosaria Anna Muscatello; Rocco A Zoccali; Gianluca Pandolfo; Paolo Mangano; Simona Lorusso; Clemente Cedro; Fortunato Battaglia; Edoardo Spina; Antonio Bruno
Journal:  Front Psychiatry       Date:  2019-10-25       Impact factor: 4.157

Review 4.  Recent Studies on Anti-Depressant Bioactive Substances in Selected Species from the Genera Hemerocallis and Gladiolus: A Systematic Review.

Authors:  Renata Matraszek-Gawron; Mirosława Chwil; Paulina Terlecka; Michał M Skoczylas
Journal:  Pharmaceuticals (Basel)       Date:  2019-11-25

Review 5.  Tryptophan Metabolism in Depression: A Narrative Review with a Focus on Serotonin and Kynurenine Pathways.

Authors:  Ana Salomé Correia; Nuno Vale
Journal:  Int J Mol Sci       Date:  2022-07-31       Impact factor: 6.208

6.  Effect of Chaihu Shugan Pills on the Pharmacokinetics of Duloxetine and its Metabolite 4-Hydroxyduloxetine in Beagle Dogs: A Herb-Drug Interaction Study.

Authors:  Yun-Tian Bi; Yao-Ren Kang; Ghulam Woshur; Hao-Zhe Ding; Shan-Shan Wang; Xiang-Jun Qiu
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-17       Impact factor: 2.650

7.  Neuroimmunology of depression.

Authors:  Erika Sarno; Adam J Moeser; Alfred J Robison
Journal:  Adv Pharmacol       Date:  2021-04-26

Review 8.  Pain management in hidradenitis suppurativa and a proposed treatment algorithm.

Authors:  Kevin T Savage; Vinita Singh; Zarine S Patel; Christine A Yannuzzi; Anne Marie McKenzie-Brown; Michelle A Lowes; Lauren A V Orenstein
Journal:  J Am Acad Dermatol       Date:  2020-09-17       Impact factor: 15.487

Review 9.  Antidepressant efficacy and side-effect burden: a quick guide for clinicians.

Authors:  Daniel Santarsieri; Thomas L Schwartz
Journal:  Drugs Context       Date:  2015-10-08

Review 10.  The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review.

Authors:  Antonio Bruno; Paolo Morabito; Edoardo Spina; Maria Rosaria Muscatello
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.